The traditional practice of classifying recurrent ovarian cancer as 'platinum-sensitive' or 'platinum-resistant' based on a six-month treatment-free interval is rapidly becoming obsolete. The introduction of maintenance therapies like PARP inhibitors is changing tumor biology and response patterns, suggesting this simple time-based distinction no longer adequately reflects the clinical reality.

For very high-risk premenopausal patients (e.g., 4+ positive nodes), clinicians may recommend continuing ovarian function suppression beyond the standard 5 years, sometimes advocating for permanent oophorectomy. This is based on clinical experience and data suggesting a more durable blunting of recurrence risk with permanent ovarian ablation.

Citing powerful long-term data from the SOFT and TEXT trials, some oncologists are leaning away from chemotherapy for premenopausal patients with intermediate Oncotype scores (e.g., <25). They argue that the substantial, proven benefits of ovarian function suppression (OFS) may be equivalent to the chemotherapy benefit seen in trials like TAILORx.

Unlike treating active diseases, prevention aims to make something *not* happen, which requires long, large, and expensive trials. Cancer also lacks a simple predictive biomarker like cholesterol for heart disease, forcing researchers to wait for the disease itself to appear as the endpoint.

An increasing proportion of metastatic breast cancer is diagnosed de novo, not as a recurrence. This seemingly negative trend is actually a positive sign that adjuvant therapies are successfully curing more patients with early-stage disease.

While the SOFT trial established a five-year standard for ovarian function suppression (OFS), new registry data indicates that continuing OFS beyond five years, often towards 10 years or natural menopause, further reduces recurrence risk. This evidence supports considering a longer duration of OFS for many premenopausal women to maximize long-term, robust benefits.

Treating genetic testing as a "magic" or specialized service reserved for counselors has caused a 30-year disservice to patients. This fear and hesitation has led to an estimated 38,000 missed opportunities annually to identify hereditary risk, resulting in larger cancers, harsher treatments, and more deaths.

While patients increasingly ask about ctDNA, clinicians are hesitant to use it for treatment decisions in ovarian cancer management. A rising ctDNA level may prompt more vigilant surveillance but does not yet trigger treatment initiation, as its correlation with survival outcomes is unproven.

Achieving remission in ovarian cancer is common, but it's often not sustainable. The strategic use of maintenance therapies, like oral PARP inhibitors, is essential to prolonging the cancer-free period and is a central focus of modern treatment.